Status:
NOT_YET_RECRUITING
Impact of Real-time MIC (Minimum Inhibitory Concentration) Reporting (<6 Hours) on β-lactam Prescription in Cases of Gram-negative Bacilli Bacteremia in ICU Patients in Real-life Settings
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Gram-negative Bacteremia
Intensive Care Patients
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Evaluate the impact of rapid, real-time (4 to 6 h) MIC reporting compared with the standard method (=diffusion antibiotic susceptibility testing) (18 to 24 h) on β-lactam prescribing in terms of the c...
Detailed Description
In the microbiology laboratory, antibiotic susceptibility is traditionally determined using the disk diffusion method on agar medium, directly from a positive blood culture bottle, which requires 18 t...
Eligibility Criteria
Inclusion
- Adult patients aged over 18 years
- Patients with a positive blood culture for Gram-negative bacilli (Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii) with results reported on weekdays before 11:00 ante meridiem (AM)
- Patients clinically suspected of infection
- Treated with empirical antibiotic therapy including a β-lactam, among the standard list of antibiotics to be tested recommended by CASFM-EUCAST (European Committee on Antimicrobial Susceptibility Testing) for Enterobacterales/Pseudomonas and included in the Reveal Rapid AST System panel
- Hospitalized in intensive care unit (ICU) for at least the next 24 hours
- Written informed consent obtained from the patient or a relative for study participation (emergency consent)
- Affiliated with the French social security system
Exclusion
- Patients receiving withdrawal or limitation of care
- Patients with an expected survival prognosis of less than 72 hours
- Patients with bloodstream infections caused by Gram-negative bacilli other than Acinetobacter baumannii, Citrobacter freundii, Citrobacter koseri, Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa
- Patients treated with antibiotic therapy not including a β-lactam
- Polymicrobial bloodstream infections
- Pregnant or breastfeeding women
- Patients under legal protection (guardianship or conservatorship)
- Participation in another interventional research study
Key Trial Info
Start Date :
October 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT07202377
Start Date
October 1 2025
End Date
November 1 2026
Last Update
October 1 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.